Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia

This post hoc analysis of clinical trial data evaluated long-term, self-reported mental and physical health-related quality of life (HRQoL) scores in schizophrenia patients receiving aripiprazole lauroxil (AL), an atypical long-acting injectable (LAI) antipsychotic approved for the treatment of schi...

Full description

Saved in:
Bibliographic Details
Published in:BMC psychiatry 2021-03, Vol.21 (1), p.164-8, Article 164
Main Authors: McEvoy, Joseph P, Weiden, Peter J, Lysaker, Paul H, Sun, Xiaowu, O'Sullivan, Amy K
Format: Article
Language:English
Subjects:
Adult
Antipsychotics
Aripiprazole
Aripiprazole - adverse effects
Aripiprazole lauroxil
Care and treatment
Chronic illnesses
Demographic aspects
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2
Diagnosis
Dosage and administration
Health aspects
Health-related quality of life
Humans
Hypertension
Long-acting injectable antipsychotics
Mental depression
Mental disorders
Mental health
Patient outcomes
Patient-reported outcomes
Patients
Population studies
Psychiatry
Psychotropic drugs
Quality of Life
Schizophrenia
Schizophrenia - drug therapy
SF-36v2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This post hoc analysis of clinical trial data evaluated long-term, self-reported mental and physical health-related quality of life (HRQoL) scores in schizophrenia patients receiving aripiprazole lauroxil (AL), an atypical long-acting injectable (LAI) antipsychotic approved for the treatment of schizophrenia in adults. The study population included 291 stable schizophrenia outpatients enrolled in 2 consecutive long-term safety studies of AL given every 4 weeks for up to 124 weeks. HRQoL was measured using the SF-36v2® Health Survey (SF-36v2) over the course of the follow-up. The primary outcome was change in SF-36v2 mental component summary (MCS) and physical component summary (PCS) scores from baseline to 124 weeks. To contextualize these scores, descriptive analyses were conducted to compare the scores with available scores for the general population as well as for other populations with chronic medical (ie, hypertension and type 2 diabetes) or psychiatric (ie, depression) conditions. Results from this post hoc analysis indicated that the mean MCS score for patients continuing AL improved significantly from baseline over 124 weeks (P 
ISSN:1471-244X
1471-244X
DOI:10.1186/s12888-021-03124-2